Paul Alhadeff,Magnus Doverskog,Maja Johansson,Thomas Meijer,Nicolaas Schipper
申请号：
US16450620
公开号：
US20190358244A1
申请日:
2019.06.24
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention is directed to a novel pharmaceutical formulation comprising 3α-ethynyl-3β-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition； and a vehicle comprising (a) 45-100% of a monoester； (b) optionally up to 51% of a diester； and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed.
